Brokers Issue 2025 Earnings Forecasts for AstraZeneca PLC (NASDAQ:AZN)

Vaseline2 weeks ago

0 3 minutes read

AstraZeneca PLC (NASDAQ:AZN – Free Report ) – Zacks Research boosted their FY2025 EPS estimates for shares of AstraZeneca in a research note issued on Thursday, September 26th. Zacks Research analyst R. Department now expects that the company will earn $4.54 per share for the year, up from their prior estimate of $4.53. The consensus estimate for AstraZeneca’s current full-year earnings is $4.05 per share. Zacks Research also issued estimates for AstraZeneca’s Q1 2026 earnings at $1.18 EPS and FY2026 earnings at $5.06 EPS.

AstraZeneca (NASDAQ:AZN – Get Your Free Report ) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.99 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.01. AstraZeneca had a net margin of 13.11% and a return on equity of 29.34%. The company had revenue of $12.45 billion during the quarter, compared to analyst estimates of $12.62 billion. In the same period last year, the firm earned $1.08 per share. The company’s quarterly revenue was up 9.1% year over year.

Want more great investment ideas?

A number of other analysts have also issued reports on the stock. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Barclays upgraded AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. Citigroup upgraded AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday, September 13th. Finally, TD Cowen boosted their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the stock. AstraZeneca has an average rating of “Buy” and a consensus price target of $89.75, according to MarketBeat .

Check out our latest report on AstraZeneca

AstraZeneca price performance

Shares of AZN stock opened at $77.91 on Monday. The firm has a 50 day moving average of $81.66 and a two hundred day moving average of $77.18. The company has a current ratio of 0.89, a quick ratio of 0.69, and a debt-to-equity ratio of 0.69. The firm has a market cap of $241.57 billion, a PE ratio of 38.19, a P/E/G ratio of 1.47 and a beta of 0.47. AstraZeneca has a one year low of $60.47 and a one year high of $87.68.

AstraZeneca cuts dividend

The company also recently announced a semiannual dividend, which was paid on Monday, September 9th. Investors of record on Friday, August 9th were given a dividend of $0.49 per share. This represents a yield of 1.8%. The ex-dividend date was Friday, August 9. AstraZeneca’s dividend payout ratio (DPR) is currently 48.04%.

Hedge funds influence AstraZeneca

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Jones Financial Companies Lllp boosted its stake in AstraZeneca by 86.7% in the fourth quarter. Jones Financial Companies Lllp now owns 506 shares of the company’s stock worth $34,000 after buying an additional 235 shares in the last quarter. CIBC Asset Management Inc raised its stake in AstraZeneca by 5.6% in the fourth quarter. CIBC Asset Management Inc now owns 223,618 shares of the company’s stock worth $15,061,000 after purchasing an additional 11,892 shares in the last quarter. Rafferty Asset Management LLC raised its stake in AstraZeneca by 35.2% in the 4th quarter. Rafferty Asset Management LLC now owns 166,959 shares of the company’s stock worth $11,245,000 after buying an additional 43,464 shares in the last quarter. Nicholas Company Inc. boosted its stake in AstraZeneca by 587.3% in the fourth quarter. Nicholas Company Inc. now owns 827,625 shares of the company’s stock worth $55,741,000 after purchasing an additional 707,215 shares in the last quarter. Finally, CIBC Private Wealth Group LLC boosted its stake in AstraZeneca by 9.3% in the fourth quarter. CIBC Private Wealth Group LLC now owns 10,424,914 shares of the company’s stock worth $708,617,000 after buying an additional 889,178 shares in the last quarter. Institutional investors own 20.35% of the company’s shares.

AstraZeneca Company Profile

(Get a free report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbilocort, Teztri Saspireph, , Pulmicort, Bevespi and Daliresp for cardiovascular, renal, metabolism and oncology.